Horm Metab Res 2022; 54(01): 25-32
DOI: 10.1055/a-1717-9332
Endocrine Care

Effects of Long-Acting Somatostatin Analogues on Lipid Metabolism in Patients with Newly Diagnosed Acromegaly: A Retrospective Study of 120 Cases

1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
,
Zheng-yuan Chen
2   Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Meng Wang
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
,
Ye-ping Yang
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
,
Yi-fei Yu
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Wen-juan Liu
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
,
Yi Wang
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Fang-fang Zeng
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
,
Wei Gong
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
,
Hong-ying Ye
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Yong-fei Wang
2   Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Yao Zhao
2   Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Li Zhang
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
,
Zhao-yun Zhang
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Min He
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
,
Yi-ming Li
1   Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, China
3   Shanghai Pituitary Tumor Center, Shanghai, China
› Author Affiliations
Funding Information This work was supported by the foundation of Shanghai Hospital Development Center (SHDC12018X04), Science and Technology Commission of Shanghai Municipality (18140901602 and 18140901600), the National Natural Science Foundation of China (No. 81770840, No. 81970716, No. 81400844 and No. 81800720) and National Project in promoting the diagnosis and treatment of major diseases by MDT.

Abstract

The short-term effects of long-acting somatostatin analogues (SSAs) on lipid profiles in patients with acromegaly are not well studied. We retrospectively analyzed the effects of SSAs on lipid profiles and associated cardiovascular risk factors in a cohort of 120 newly diagnosed acromegaly patients. In this study, 69 females and 51 males were included. These patients were treated with either octreotide LAR (OCT) or lanreotide SR (LAN) for 3 months. After SSAs treatment, both GH and IGF-1 significantly decreased (p<0.001). Triglyceride (TG), total to high-density lipoprotein cholesterol (HDL-C) ratio, and lipoprotein (a) [Lp(a)] levels were significantly decreased, while HDL-C levels were increased (p<0.05). The reduction of mean serum GH (GHm) was positively associated with the decrease of TG (r=0.305, p=0.001) and Lp(a) (r=0.257, p=0.005), as well as the increase of HDL-C (r=−0.355, p<0.001). The changes of lipid profiles were observed only in OCT group, but not in LAN group. In addition, systolic blood pressure (SBP) had significantly declined after SSAs treatment, with an average reduction of 4.4 mmHg (126.7±1.28 vs. 122.3±1.44 mmHg, p=0.003), while no change was observed regarding diastolic blood pressure (DBP) (p>0.05). Fasting insulin, fasting C-peptide, and HOMA-IR were significantly decreased after SSAs treatment. In conclusion, our current study revealed that short-term SSAs treatment improves lipid profiles and other cardiovascular risk factors in patients with acromegaly.



Publication History

Received: 11 May 2021

Accepted after revision: 30 November 2021

Article published online:
05 January 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany